March 2011 – Lacerta Bio

EU Not Jazzed about Fibromyalgia Either

Post author:Carlos
Post published:March 25, 2011
Post category:Biotech Drug Development Europe

It was recently announced that the EMA has rejected Xyrem for the treatment of fibromyalgia. Interestingly, Xyrem is already approved in Europe for the treatment of narcolepsy with cataplexy. We…

Impressions from Natural Products ExpoWest 2011

Post author:Carlos
Post published:March 15, 2011
Post category:Conferences Government

This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from…

Cost of drug development may not be $1 billion after all

Post author:Carlos
Post published:March 7, 2011
Post category:Biotech Drug Development Pharmaceutical

Drug development costs of $1 billion are often quoted. A new study estimates costs to be much lower, based on a different statistical approach.

Get in touch